TECX Overview

Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Its product candidates are TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. Its second development candidate, TX2100, is a VHH-Fc fusion antagonist antibody that binds to the APJ receptor (APLNR), also known as the apelin receptor. Its APJ is a differentiated approach for the treatment of hereditary hemorrhagic telangiectasia (HHT) and is a selective anti-angiogenic target that is primarily expressed in endothelial cells.

Wall Street analysts forecast TECX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TECX is81.00 USD with a low forecast of 60.00 USD and a high forecast of 101.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Tectonic Therapeutic Inc revenue for the last quarter amounts to -27.30M USD, increased 49.20

Tectonic Therapeutic Inc. EPS for the last quarter amounts to -18432000.00 USD, increased 40.59

Tectonic Therapeutic Inc (TECX) has 60 emplpoyees as of July 08 2026.

Today TECX has the market capitalization of 689.39M USD.